Oxford Biomedica announces update to agreement with Sio Gene Therapies
31 janv. 2022 16h13 HE
|
Oxford BioMedica plc
Oxford Biomedica announces that Sio Gene Therapies intends to cease the license agreement for gene therapy programme in Parkinson’s disease Negligible financial impact on Oxford Biomedica in the...
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with Homology Medicines as 20% owner
28 janv. 2022 02h39 HE
|
Oxford BioMedica plc
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the US with...
John Dawson to retire from Oxford Biomedica
17 janv. 2022 02h00 HE
|
Oxford BioMedica plc
John Dawson to retire from Oxford Biomedica Oxford, UK – 17 January 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group” or “the Company”) a leading gene and cell therapy company,...
Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene Therapy Treatment for Cystic Fibrosis
19 oct. 2021 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene Therapy Treatment for Cystic Fibrosis Oxford, UK – 19 October 2021: Oxford Biomedica plc (LSE:OXB)...
Oxford Biomedica Plc INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021
22 sept. 2021 07h00 HE
|
Oxford BioMedica plc
OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021 Oxford Biomedica delivers record first half results Oxford, UK – 22 September 2021: Oxford Biomedica plc (“Oxford...
Oxford Biomedica announces strategic investment by Serum Life Sciences Ltd
22 sept. 2021 07h00 HE
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...
Oxford Biomedica Appoints Dr. Michael Hayden as Non-Executive Director
15 juil. 2021 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica Appoints Dr. Michael Hayden as Non-Executive Director Oxford, UK – 15 July, 2021: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy...
Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine
18 mai 2021 07h00 HE
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...
Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture of COVID-19 Vaccine
18 mai 2021 02h00 HE
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...
Oxford Biomedica plc Preliminary results for the year ended 31 December 2020
15 avr. 2021 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica plcPreliminary results for the year ended 31 December 2020 Saving Lives Oxford, UK – 15 April 2021: Oxford Biomedica plc (LSE: OXB), (“OXB” or “the Group”), a leading cell and...